CAS NO: | 412950-08-4 |
包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cas No. | 412950-08-4 |
别名 | 2-[[(2,3-二氟苯基)甲基]硫基]-N-[1-(2-甲氧基乙基)-4-哌啶基]-4-氧代-N-[[4'-(三氟甲基)[1,1'-联苯]-4-基]甲基]-1(4H)-喹啉乙酰胺,SB 659032 |
Canonical SMILES | O=C(N(C1CCN(CCOC)CC1)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)CN4C(SCC5=CC=CC(F)=C5F)=CC(C6=C4C=CC=C6)=O |
分子式 | C40H38F5N3O3S |
分子量 | 735.81 |
溶解度 | DMSO : 86.67 mg/mL (117.79 mM);Water :< 0.1 mg/mL (insoluble) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM. [1]. Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A? inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094. |